Get the Stockscreener App
1.17
6.36%
0.07
After Hours:
1.17
Akoya Biosciences Inc stock is traded at $1.17, with a volume of 111.18K.
It is up +6.36% in the last 24 hours and down -31.18% over the past month.
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.
See More
Previous Close:
$1.10
Open:
$1.1
24h Volume:
111.18K
Relative Volume:
0.37
Market Cap:
$59.28M
Revenue:
$96.63M
Net Income/Loss:
$-63.32M
P/E Ratio:
-0.8014
EPS:
-1.46
Net Cash Flow:
$-54.55M
1W Performance:
-1.68%
1M Performance:
-31.18%
6M Performance:
-59.23%
1Y Performance:
-70.00%
1-Day Range:
$1.10
$1.20
1-Week Range:
$1.02
$1.2399
52-Week Range:
$1.01
$4.65
Akoya Biosciences Inc Stock (AKYA) Company Profile
Name
Akoya Biosciences Inc
Sector
Industry
Phone
855.896.8401
Address
100 CAMPUS DRIVE, MARLBOROUGH
Compare AKYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
1.17 | 59.28M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
478.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
199.88 | 57.39B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
93.31 | 45.22B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
214.08 | 31.43B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
79.79 | 15.88B | 3.90B | 392.30M | 288.10M | 1.95 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-06-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-06-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-21-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Feb-02-23 | Initiated | UBS | Buy |
| Nov-03-22 | Initiated | CapitalOne | Overweight |
| Oct-06-22 | Initiated | Stephens | Overweight |
| Jun-22-22 | Initiated | BTIG Research | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| May-11-21 | Initiated | Canaccord Genuity | Buy |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Morgan Stanley | Overweight |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Akoya Biosciences Inc Stock (AKYA) Latest News
Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders - Business Wire
Akoya Biosciences (NASDAQ:AKYA) Given New $1.65 Price Target at Piper Sandler - Defense World
Tikvah Management Calls on Quanterix to Explain the Egregious Te - GuruFocus
Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences - Bluefield Daily Telegraph
Quanterix Faces Investor Backlash: $30M Convertible Notes Deal Under Fire - Stock Titan
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Akoya Biosciences stock hits 52-week low at $1.07 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.07 amid market challenges - Investing.com India
Quanterix Under Fire: Top Investor Warns of 'Value Destructive' $30M Deal with Struggling Akoya - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – OPTN, SLRN, AKYA, SHYF - GlobeNewswire Inc.
Akoya BiosciencesOn April 2, Entered Securities Purchase Agreement With Quanterix Corporation - MarketScreener
Spatial Genomics and Transcriptomics Industry Analysis Report 2025, Featuring Detailed Profiles of Leading Players10x Genomics, Bruker Corp., Akoya Biosciences, and Bio-Techne Among OthersResearchAndMarkets.com - Bluefield Daily Telegraph
Akoya Biosciences and Team SAMBAI Announce Selection of the - GlobeNewswire
Akoya Biosciences And Team SAMBAI Select PhenoCycler-Fusion For Cancer Equity Research - Nasdaq
Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities - Yahoo Finance
Short Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Decreases By 30.8% - The AM Reporter
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Down 30.8% in March - Defense World
Akoya Biosciences stock hits 52-week low at $1.39 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.39 amid market challenges - Investing.com India
This Waters Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Akoya Biosciences’ (AKYA) Equal Weight Rating Reaffirmed at Stephens - Defense World
Akoya Biosciences Shares Fall After Downgrade From Stephens - MarketScreener
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
This Brown & Brown Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Stephens Downgrades Akoya Biosciences to Equalweight From Overweight, Price Target is $1.80 - Marketscreener.com
Tikvah to oppose Quanterix-Akoya Biosciences merger By Investing.com - Investing.com Australia
Tikvah to oppose Quanterix-Akoya Biosciences merger - Investing.com India
Tikvah Management Announces Intention to Vote AGAINST Quanterix’s Proposed Merger with Akoya Biosciences - Business Wire
Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences - Marketscreener.com
Key Investor Fights Back: Quanterix Merger Under Fire Over Valuation Concerns - Stock Titan
Akoya Biosciences (AKYA) to Release Quarterly Earnings on Monday - Defense World
Akoya Biosciences Reports 2024 Financial Results - TipRanks
Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates - MSN
Stephens Reaffirms “Overweight” Rating for Akoya Biosciences (NASDAQ:AKYA) - The AM Reporter
Akoya Biosciences (NASDAQ:AKYA) Receives Overweight Rating from Stephens - Defense World
Akoya Biosciences Shares Down 6.4% After Stock Offering… -June 08, 2023 at 10:10 am EDT - Marketscreener.com
Akoya Biosciences stock hits 52-week low at $1.43 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.43 amid market challenges - Investing.com Australia
Akoya: Q4 Earnings Snapshot - Milford Mirror
Akoya Biosciences earnings missed by $0.01, revenue topped estimates - Investing.com Australia
Akoya Biosciences, Inc. Q4 Loss Decreases, But Misses Estimates - Nasdaq
Akoya Biosciences, Inc. SEC 10-K Report - TradingView
Kent Lake urges Quanterix to address questions regarding Akoya deal -March 17, 2025 at 04:28 pm EDT - Marketscreener.com
Akoya Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Akoya Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results Amid Pending Acquisition by Quanterix Corporation - Nasdaq
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results - GlobeNewswire
Quanterix Merger Under Fire: Top Investor Reveals Shocking 82% Value Disparity - Stock Titan
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today’s Earnings Call - Bluefield Daily Telegraph
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Rating of “Hold” by Brokerages - Defense World
Quanterix Shareholder Opposes Proposed Akoya Biosciences Merger -March 11, 2025 at 10:40 am EDT - Marketscreener.com
Quanterix Merger Under Fire: 7.25% Stakeholder Reveals Shocking Valuation Concerns - StockTitan
Akoya Biosciences Inc Stock (AKYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Akoya Biosciences Inc Stock (AKYA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| McKelligon Brian | President and CEO |
Jun 11 '24 |
Sale |
2.08 |
7,500 |
15,630 |
224,733 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
232,233 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Sale |
2.01 |
7,500 |
15,064 |
224,733 |
1.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):